

Structural basis for tRNA methylthiolation by the radical SAM enzyme MiaB

Authors: Olga A. Esakova^{1,*}, Tyler L. Grove^{2,*}, Neela H. Yennawar⁴, Arthur J. Arcinas^{3,6}, Bo Wang¹, Carsten Krebs^{1,3}, Steven C. Almo², and Squire J. Booker^{1,3,5*}

Affiliations: The ¹Department of Chemistry, the ³Department of Biochemistry and Molecular Biology, ⁴The Huck Institutes of the Life Sciences, and the ⁵Howard Hughes Medical Institute, The Pennsylvania State University, University Park, Pennsylvania 16802, USA.

The ²Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York

⁶Present address: AGC Biologics, Seattle, WA

Corresponding authors: squire@psu.edu, oe3@psu.edu, and tylergrove223@gmail.com

One Sentence Summary: First X-ray crystal structures of a methylthiotransferase that acts on tRNA

Summary Paragraph

Numerous post-transcriptional modifications of transfer RNAs (tRNAs) play vital roles in translation. The 2-methylthio-*N*⁶-isopentenyladenosine (ms²i⁶A) modification occurs at position 37 (A37) in tRNAs that contain adenine in position 36 of the anticodon, and serves to promote efficient A:U codon-anticodon base-pairing and to prevent unintended base-pairing by near cognates, thus enhancing translational fidelity.¹⁻⁴ The ms²i⁶A modification is installed onto isopentenyladenosine (i⁶A) by MiaB, a radical S-adenosylmethionine (SAM) methylthiotransferase (MTTase). As a radical SAM protein, MiaB contains one [Fe₄S₄]_{RS} cluster used in the reductive cleavage of SAM to form a 5'-deoxyadenosyl 5'-radical (5'-dA•), which is responsible for removing the C² hydrogen of the substrate.⁵ MiaB also contains an auxiliary [Fe₄S₄]_{aux} cluster, which has been implicated in sulfur transfer to C² of i⁶A37.⁶⁻⁹ How this transfer takes place is largely unknown. Herein, we present several structures of MiaB from *Bacteroides uniformis* (BuMiaB). These structures are consistent with a two-step mechanism, in which one molecule of SAM is first used to methylate a bridging μ-sulfido ion of the auxiliary cluster. In the second step, a second SAM molecule is cleaved to a 5'-dA•, which abstracts the C² hydrogen of the substrate, but after C² has undergone rehybridization from sp² to sp³. This work advances our understanding of how enzymes functionalize inert C–H bonds with sulfur.

Introduction

MiaB catalyzes the final step in the biosynthesis of the hypermodified nucleoside ms²i⁶A, which is the attachment of a methylthio (–SCH₃) group at C² of i⁶A37 in tRNAs that contain adenine in position 36 of the anticodon (**Fig. 1a**).³ The human ortholog, CDK5RAP1, is mitochondrially located and responsible for modifying Ser^(AGN), Phe, Tyr, and Trp of mitochondrial tRNAs at nucleotide i⁶A37.^{10,11} It also regulates the activity of the cyclin-dependent kinase 5 and is linked to functions of the central nervous system. Moreover, it is implicated in a number of cancers.^{12,13} Another related class of methylthiotransferases (MTTases), designated MtaB-like^{14,15}, acts on C² of N⁶-(threonylcarbamoyl)adenosine (t⁶A), also found at position 37, but in tRNA^{Lys(UUU)} (**Fig. 1b**). The loss of function or downregulation of one such MTTase, CDKAL1, is one of the greatest risk factors across all ethnic groups for the development of type 2 diabetes.¹⁶ Lastly, RimO is the only known MTTase that targets a protein, which in *E. coli*, is C³ of Asp89 of protein S12 of the 30S subunit of the bacterial ribosome (**Fig. 1c**).¹⁷⁻¹⁹

MiaB, like other known MTTases, contains an [Fe₄S₄]_{RS} cluster and an [Fe₄S₄]_{aux} cluster, both of which are required for its function. The [Fe₄S₄]_{RS} cluster is responsible for the reductive cleavage of SAM to afford the 5'-dA•, while the [Fe₄S₄]_{aux} cluster is believed to be involved in sulfur incorporation. Biochemical studies suggest that a methyl group from SAM is first transferred to an undetermined sulfur species associated with the [Fe₄S₄]_{aux} cluster. Subsequently, the nascent methylthio group is transferred intact to C² of i⁶A37 in a radical-dependent reaction.^{6,20,21} Despite the importance of tRNA methylthiolation in human health,¹⁶ how these MTTases accomplish this difficult reaction is largely unknown.

BuMiaB domain architecture

BuMiaB is composed of three domains (**Fig. 2a and Extended Data Table 1**): an N-terminal MTTase domain, an RS domain, and a C-terminal TRAM domain. The MTTase domain (residues 1 to 139, **Fig. S1a**) contains Cys27, Cys63 and Cys97, which coordinate three of the irons of the $[\text{Fe}_4\text{S}_4]_{\text{aux}}$ cluster (**Extended Data Fig. 3a**), while the RS domain (residues 162-396, **Fig. S1b**) exhibits a conserved core fold that consists of a shortened $(\beta\alpha)_6$ triosephosphate isomerase (TIM) barrel. The RS domain contains Cys171, Cys173 and Cys178, which coordinate three of the irons of the $[\text{Fe}_4\text{S}_4]_{\text{RS}}$ cluster. The C-terminal TRAM domain (residues 397-457, **Fig. S1c**), which was proposed to play an important role in RNA binding, is composed of a twisted antiparallel five-stranded β -sheet that is positioned over the RS domain.^{22,23} The overall architecture of *BuMiaB* is similar to that of RimO from *Thermotoga maritima* (*TmRimO*; **PDB:4JC0**) (**Extended Data Fig. 1**). The structure of *BuMiaB* in the absence of substrates shows that the $[\text{Fe}_4\text{S}_4]_{\text{aux}}$ and $[\text{Fe}_4\text{S}_4]_{\text{RS}}$ clusters are connected by a pentasulfide bridge (**Extended Data Fig. 1a**), as was observed in the *TmRimO* structure.⁸

RNA interactions and binding specificity

In the structures of *BuMiaB* complexed with a 13-mer (nucleotides 29-41) or a 17-mer (nucleotides 27-43) RNA substrate surrogate derived from the *Bacteroides uniformis* (*Bu*) tRNA^{Phe} anticodon stem loop (ACSL) sequence, all three domains of the protein interact with the RNA (**Extended Data Fig. 2b**). One structure, determined to 1.5 Å resolution (**Extended Data Table 1 and Table S1**), contains *BuMiaB* in the presence of 5'-deoxyadenosine plus methionine (5'dAH+Met) and the 13-mer. This structure shows that the central part of the enzyme contains a deep cleft (~26 Å) formed at the interface of all three domains. Two positively charged regions in the cleft are in close contact with the phosphates of the RNA backbone, forming strong

electrostatic interactions (**Extended Data Fig. 2c**). In addition, the surface of the cleft, where the 13-mer RNA is bound, contains many highly conserved amino acids (**Extended Data Fig. 2d**).

RNA bases 33 to 37 form the anticodon loop (**Extended Data Figs. 3, 4**). This loop is supported by a canonical double-stranded region exhibiting base-pairing between nucleotides 29 to 32 from the 5'-side of the RNA with nucleotides 41 to 38 on the 3'-side, respectively. This base-pairing is similar to that of full-length tRNA^{Phe} in complex with MiaA (**PDB: 2ZM5**), suggesting that the tRNA maintains its native secondary structure in complex with *Bu*MiaB (**Extended Data Figs. 3a, 4a**). The RNA backbone from nucleotides 29 to 32 is contacted by a loop spanning amino acid residues 408–413 of the TRAM domain. Lys409 and Arg410 from this loop are within H-bonding distance of the RNA (**Fig. 2b, Extended Data Fig. 3b**). Arg410 supports a turn of the RNA between nucleotides G30 and C32 by electrostatic interactions with the phosphate oxygens of C32 and U33 (**Figs. 2b, 2c**). Ser446 from another loop of the TRAM domain is within H-bonding distance of the phosphate oxygen of C32. MiaB in complex with the 13-mer RNA has induced a U-turn that is not seen in the full-length tRNA in complex with MiaA (**Fig. 2b, Extended Data Figs. 3a, 4a**).²⁴

U33 is conserved in all tRNAs, and our structures show a unique binding mode of this nucleotide with MiaB's TRAM domain, demonstrated to be important for substrate selection²³⁻²⁵. The U33 base is immersed in a positively charged pocket lined by Lys409, Arg410 and Lys451, conserved residues that provide selectivity for the U33 base (**Extended Data Fig. 2d**). Other residues from the pocket include Ser408 and Gln414, both of which coordinate to N³ of U33 through a water molecule. The amide backbone nitrogen atoms of Lys409 and Arg410 form H-bonds with the C² oxygen atom of U33. C⁵ and C⁶ of U33 are in a hydrophobic interaction

with the side-chain of Val426 and the methyl group of Thr449. The side-chain of Arg410 covers the U33 binding pocket en route to interacting with the phosphate backbone (**Figs. 2b, 2c**).

Sequence analysis of tRNAs possessing ms²i⁶A37 shows a conserved adenosine at position 36, the last nucleotide of the anticodon.^{15,26,27} The recognition motif for A36 is located in the β 27 strand of the RS domain and includes Phe348 and Phe350, both of which form van der Waals interactions with A36. Phe348 forms an edge-to-face interaction with C⁶ of A36, and Phe350 forms an edge-to-edge interaction with C² of A36 (**Figs. 2d, 2e**). As seen in structures of other RNA/protein complexes that recognize an adenine,^{28,29} the interaction between Phe350 and C² of A36 may be important for base recognition. Unlike adenine, the other bases have hydrophilic groups attached to C² (i.e., O for C, NH₂ for U and G), which can disrupt van der Waals interactions. A36 points towards the stem of the ACSL and participates in base-stacking interactions with A38. In contrast to A36 and i⁶A37, nucleotides 34 and 35, which are the first and second nucleotides of the anticodon, are not conserved in tRNAs that possess ms²i⁶A37 and do not show base-specific interactions (**Extended Data Figs. 5a, 5b**).

The immediate base after the anticodon, i⁶A37, is recognized as the substrate by its isopentenyl group, which explains why MiaB only acts on A37 that has been isopentenylated.³⁰ The isopentenyl group makes hydrophobic contacts with the methyl groups of Thr251 and Thr252, which are connected by a cis-peptide bond needed to support these interactions (**Extended Data Fig. 5c**). The methylene groups of Cys27 and Met29 from the MTTase domain, and Leu213 and Gln215 from the RS domain, complete the hydrophobic pocket for the isopentenyl group. The only direct H-bond interaction is between the carbamoyl oxygen of Gln28 and N⁶ of i⁶A37. A model of *Bu*MiaB in complex with the full-length of tRNA^{Phe} was constructed, revealing two regions in the MTTase domain that are potentially involved in tRNA

engagement: the highly conserved residues Gln71 and Lys72, and the positively charged loop from residues 84 to 88 (KKKKR) (**Extended Data Fig. 6**).

Active site and reaction mechanism

Two molecules of SAM are expended for each cycle of MiaB catalysis, resulting in one molecule of SAH and one molecule each of 5'-dAH and Met. The first molecule of SAM binds to the $[\text{Fe}_4\text{S}_4]_{\text{RS}}$ cluster (**Extended Data Fig. 7a**) and donates its methyl group to an acceptor, forming SAH in the process (**Fig. 4, step 1**). The most likely acceptor is a μ_2 -sulfido ion from the auxiliary cluster, given its close proximity to the sulfur of SAH (4.3 Å) in the SAH-bound structure with the 13-mer RNA substrate (**Fig. 3a**), or the methyl group of SAM (3.4 Å) in the SAM-bound structure with the 17-mer (**Fig. 3b**).

The structure of *BuMiaB* with SAM and the 17-mer represents the next snapshot in catalysis (**Fig. 3b**), which takes place after SAH leaves the active site and is replaced by a second molecule of SAM (**Fig. 4, steps 2 and 3**). The structure, obtained from crystals grown in the presence of excess SAM and the 17-mer, was determined to a resolution of 2.24 Å (**Extended Data Table 1, Table S1**). The $[\text{Fe}_3\text{S}_4]_{\text{aux}}$ cluster does not show extra density that can be attributed to a transferred methyl group, although this density would be difficult to discern at this resolution. C^2 of i^6A is 5.6 Å from the closest sulfide of the $[\text{Fe}_3\text{S}_4]_{\text{aux}}$ cluster. However, the position of i^6A changes in the structure of *BuMiaB* co-crystallized with the 13-mer and 5'-dAH+Met. This complex mimics the step in which SAM is reductively cleaved to form the 5'-dA• and Met (**Fig. 4, steps 4, 5 and 6**). In the structure of *BuMiaB* with the 17-mer and SAM, Arg66 is H-bonded to N^3 of i^6A (**Fig. 3b**), while in the structure with the 13-mer and 5'-dAH+Met (**Fig. 3c, Extended Data Fig. 7b**), N^3 of i^6A loses its direct interaction with Arg66

and interacts through a water molecule. The electron density around N³ of i⁶A appears to be extended in the direction of the water molecule in the structure of *BuMiaB* with 5'-dAH+Met and the 13-mer, suggesting that N³ moves slightly out of the plane of adenosine (**Fig. 3c**).

In the structure of *BuMiaB* with the 13-mer and 5'-dAH+Met, C² of i⁶A sits between C^{5'} of 5'-dAH and a μ_2 -sulfido ion of the [Fe₃S₄]_{aux} cluster at distances of 3.1 and 3.3 Å, respectively (**Fig. 3c, Extended Data Fig. 7b**). The angle between C^{5'} of 5'-dAH and C² is 108 ± 1.5° (1.5 Å resolution) and more suitable for H-atom abstraction from an sp³-hybridized carbon (109.5°) than from an sp²-hybridized carbon (120°). The suggested change in hybridization at C² may be promoted by protonation of N³ of i⁶A by Arg66 through an intervening water molecule or by polarization of the adenine ring π -system mediated by H-bonding. Consistent with this role in catalysis, replacement of Arg66 with Gln does not inhibit methyl transfer from SAM to the cluster in solution (**Extended Data Fig. 8a**), but it does completely abolish formation of ms²i⁶A37 (**Extended Data Fig. 8b-e**).

An additional structure (1.4 Å resolution) of *BuMiaB* in the presence of 5'-dAH+Met and the 13-mer was also determined at 1.4 Å resolution, but after pre-methylating *BuMiaB* with SAM (**Extended Data Table 1, Table S1**). As in the previous structure of non-pre-methylated *BuMiaB* with 5'-dAH+Met and the 13-mer, the pre-methylated *BuMiaB* structure demonstrates distorted electron density around N³ of i⁶A (**Extended Data Fig. 9a**). We also observe extended electron density on one of the sulfides of the [Fe₃S₄]_{aux} cluster, which we posit is the transferred methyl group (**Fig. 3d, Extended Data 9b**). Such a localization of the methyl group, which might be driven by a steric clash with the i⁶A substrate, necessitates that iron dissociate from the auxiliary cluster, as has recently been demonstrated spectroscopically.⁷ After abstraction of the C² hydrogen atom, the resulting unpaired electron at C² is transferred into the auxiliary cluster

with concomitant rearomatization of i⁶A37 (**Fig. 4, steps 7 and 8**). This step would result in reduction of an Fe³⁺ to Fe²⁺ and dissociation of the methylthio group from the fragmented auxiliary cluster, which is suggested to be [Fe₃S₃]¹⁺.

Discussion

We have, for the first time, determined structures of an MTTase in the presence of its macromolecular substrate. *BuMiaB* shows exquisite selectivity for i⁶A37, and various elements of the structure detail how this selectivity is achieved. Although all three domains of the protein contribute to RNA binding, the TRAM domain contributes conserved amino acids that select for U33, which is conserved in all tRNAs. A36 is found in all tRNAs that undergo the ms²i⁶A modification, and is recognized by two Phe residues contributed by the RS domain, which also select against all other nucleotides at this position. Importantly, i⁶A37 is recognized predominantly by its isopentenyl modification, which is consistent with *MiaB*'s inability to modify A37 that is not isopentenylated.

The *MiaB* reaction takes place in two distinct half-reactions, and it appears that one SAM binding site supports both of these steps, as has been observed for the class A RS methylases RlmN and Cfr.³¹ The structure of *BuMiaB* with bound SAM plus the 17-mer RNA substrate shows that SAM binds to the [Fe₄S₄]_{RS} cluster with its methyl group positioned 3.4 Å from a bridging μ_2 -sulfido ion of an [Fe₃S₄]_{aux} cluster, an arrangement that is consistent with methylation of the [Fe₃S₄]_{aux} cluster by a standard S_N2 mechanism. In the second half-reaction, an intact methylthio group is transferred to C² of i⁶A37 in a radical-dependent reaction. The structure of *BuMiaB* in the presence of the 13-mer RNA substrate and 5'-dAH+Met provides insight into how this unusual reaction takes place. C² of the adenine base is sandwiched between

the methylated sulfide ion of the $[\text{Fe}_3\text{S}_4]_{\text{aux}}$ cluster and the 5'-carbon of 5'-dAH at angles of $\sim 108.5^\circ$, suggestive of tetrahedral geometry. The structure suggests that the C^2 hydrogen is abstracted upon C^2 rehybridization from sp^2 to sp^3 , which would circumvent the unfavorable homolytic bond-dissociation energy associated with cleaving the $\text{C}^2\text{--H}$ bond,^{32,33} and also satisfy the spatial constraints associated with subsequent functionalization. This rehybridization is suggested to be promoted through attack at C^2 by the methylated sulfide ion of the auxiliary cluster. Our studies herein provide unprecedented insight into the mechanism of tRNA methylthiolation. A better understanding of the reaction catalyzed by RimO, and in particular how its TRAM domain is used to recognize a protein substrate, awaits better X-ray structures of that enzyme.

REFERENCES

- 1 Connolly, D. M. & Winkler, M. E. Genetic and physiological relationships among the *miaA* gene, 2-methylthio-N⁶-(δ 2-isopentenyl)-adenosine tRNA modification, and spontaneous mutagenesis in *Escherichia coli* K-12. *J. Bacteriol.* **171**, 3233-3246 (1989).
- 2 Connolly, D. M. & Winkler, M. E. Structure of *Escherichia coli* K-12 *miaA* and characterization of the mutator phenotype caused by *miaA* insertion mutations. *J. Bacteriol.* **173**, 1711-1721 (1991).
- 3 Esberg, B., Leung, H.-C. E., Tsui, H.-C. T., Björk, G. R. & Winkler, M. E. Identification of the *miaB* gene, involved in methylthiolation of isopentenylated A37 derivatives in the tRNA of *Salmonella typhimurium* and *Escherichia coli*. *J. Bacteriol.* **181**, 7256-7265 (1999).
- 4 Urbonavicius, J., Qian, Q., Durand, J. M. B., Hagervall, T. G. & Björk, G. R. Improvement of reading frame maintenance is a common function for several tRNA modifications. *EMBO J.* **20**, 4863-4873 (2001).
- 5 Arcinas, A. J. *Mechanistic Studies of the radical S-adenosyl-L-methionine (SAM) tRNA Methylthiotransferase MiaB* Ph.D. thesis, The Pennsylvania State University, (2016).
- 6 Landgraf, B. J., Arcinas, A. J., Lee, K.-H. & Booker, S. J. Identification of an intermediate methyl carrier in the radical S-adenosylmethionine methylthiotransferases RimO and MiaB. *J. Am. Chem. Soc.* **135**, 15404-15416 (2013).
- 7 Zhang, B. *et al.* First step in catalysis of the radical S-adenosylmethionine methylthiotransferase MiaB yields an intermediate with a $[\text{3Fe-4S}](0)$ -like auxiliary cluster. *J Am Chem Soc* **142**, 1911-1924, doi:10.1021/jacs.9b11093 (2020).
- 8 Forouhar, F. *et al.* Two Fe-S clusters catalyze sulfur insertion by radical-SAM methylthiotransferases. *Nat. Chem. Biol.* **9**, 333-338 (2013).

232 9 Hernández, H. L. *et al.* MiaB, a bifunctional radical-S-adenosylmethionine enzyme involved in the
233 thiolation and methylation of tRNA, contains two essential [4Fe-4S] clusters. *Biochemistry* **46**,
234 5140-5147 (2007).

235 10 Reiter, V. *et al.* The CDK5 repressor CDK5RAP1 is a methylthiotransferase acting on nuclear and
236 mitochondrial RNA. *Nuc. Acids Res.* **40**, 6235–6240 (2012).

237 11 Wei, F. Y. *et al.* Cdk5rap1-mediated 2-methylthio modification of mitochondrial tRNAs governs
238 protein translation and contributes to myopathy in mice and humans. *Cell Metab.* **21**, 428-442,
239 doi:10.1016/j.cmet.2015.01.019 (2015).

240 12 Adami, R. & Bottai, D. S-adenosylmethionine tRNA modification: unexpected/unsuspected
241 implications of former/new players. *Int J Biol Sci* **16**, 3018-3027, doi:10.7150/ijbs.49302 (2020).

242 13 Dhaven, R. & Tsai, L.-H. A decade of CDK5. *Nat. Rev. Mol. Cell Biol.* **2**, 749–759 (2001).

243 14 Arragain, S. *et al.* Identification of eukaryotic and prokaryotic methylthiotransferase for
244 biosynthesis of 2-methylthio-N⁶-threonylcarbamoyladenosine in tRNA. *J. Biol. Chem.* **285**,
245 28425-28433 (2010).

246 15 Anton, B. P. *et al.* Functional characterization of the YmcB and YqeV tRNA
247 methylthiotransferases of *Bacillus subtilis*. *Nucleic Acids Res.* **38**, 6195–6205 (2010).

248 16 Landgraf, B. J., McCarthy, E. L. & Booker, S. J. Radical S-adenosylmethionine enzymes in human
249 health and disease. *Annu. Rev. Biochem.* **85**, 485–514, doi:10.1146/annurev-biochem-060713-
250 035504 (2016).

251 17 Anton, B. P. *et al.* RimO, a MiaB-like enzyme, methylthiolates the universally conserved Asp88
252 residue of ribosomal protein S12 in *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* **105**, 1826–1831
253 (2008).

254 18 Landgraf, B. J. & Booker, S. J. Stereochemical course of the reaction catalyzed by RimO, a radical
255 SAM methylthiotransferase. *J Am Chem Soc* **138**, 2889-2892, doi:10.1021/jacs.5b11035 (2016).

256 19 Arragain, S. *et al.* Post-translational modification of ribosomal proteins: Structural and functional
257 characterization of RimO from *Thermotoga maritima*, a radical S-adenosylmethionine
258 methylthiotransferase. *J. Biol. Chem.* **285**, 5792–5801 (2010).

259 20 Agris, P. F., Armstrong, D. J., Schafer, K. P. & Soll, D. Maturation of a hypermodified nucleoside in
260 transfer RNA. *Nucleic Acids Res.* **2**, 691-698 (1975).

261 21 Molle, T. *et al.* Redox Behavior of the S-Adenosylmethionine (SAM)-Binding Fe-S Cluster in
262 Methylthiotransferase RimO, toward Understanding Dual SAM Activity. *Biochemistry* **55**, 5798-
263 5808, doi:10.1021/acs.biochem.6b00597 (2016).

264 22 Lee, T. T., Agarwalla, S. & Stroud, R. M. A unique RNA Fold in the RumA-RNA-cofactor ternary
265 complex contributes to substrate selectivity and enzymatic function. *Cell* **120**, 599-611,
266 doi:10.1016/j.cell.2004.12.037 (2005).

267 23 Anantharaman, V., Koonin, E. V. & Aravind, L. TRAM, a predicted RNA-binding domain, common
268 to tRNA uracil methylation and adenine thiolation enzymes. *Fems Microbiol Lett* **197**, 215-221,
269 doi:10.1111/j.1574-6968.2001.tb10606.x (2001).

270 24 Chimnaronk, S. *et al.* Snapshots of dynamics in synthesizing N(6)-isopentenyladenosine at the
271 tRNA anticodon. *Biochemistry* **48**, 5057-5065, doi:10.1021/bi900337d (2009).

272 25 Anantharaman, V., Koonin, E. V. & Aravind, L. Comparative genomics and evolution of proteins
273 involved in RNA metabolism. *Nucleic Acids Res* **30**, 1427-1464, doi:10.1093/nar/30.7.1427
274 (2002).

275 26 Nishimura, S. *Transfer RNA: Structure, Properties, and Recognition*. 59-29 (Cold Spring Harbor
276 Laboratory, 1979).

277 27 Boccaletto, P. *et al.* MODOMICS: a database of RNA modification pathways. 2017 update.
278 *Nucleic Acids Res* **46**, D303-D307, doi:10.1093/nar/gkx1030 (2018).

- 28 Ellis, J. J., Broom, M. & Jones, S. Protein-RNA interactions: structural analysis and functional classes. *Proteins* **66**, 903-911, doi:10.1002/prot.21211 (2007).
- 29 Jones, S., Daley, D. T., Luscombe, N. M., Berman, H. M. & Thornton, J. M. Protein-RNA interactions: a structural analysis. *Nucleic Acids Res* **29**, 943-954, doi:10.1093/nar/29.4.943 (2001).
- 30 Pierrel, F., Douki, T., Fontecave, M. & Atta, M. MiaB protein is a bifunctional radical-S-adenosylmethionine enzyme involved in thiolation and methylation of tRNA. *J. Biol. Chem.* **279**, 47555-47653 (2004).
- 31 Grove, T. L., Radle, M. I., Krebs, C. & Booker, S. J. Cfr and RlmN contain a single [4Fe-4S] cluster, which directs two distinct reactivities for S-adenosylmethionine: methyl transfer by S_N2 displacement and radical generation. *J. Am. Chem. Soc.* **133**, 19586-19589 (2011).
- 32 Kim, S., Meehan, T. & Schaefer, H. F., III. Hydrogen-atom abstraction from the adenine-uracil base pair. *J. Phys. Chem. A.* **111**, 6806-6812 (2007).
- 33 Zierhut, M., Roth, W. & Fischer, I. Dynamics of H-atom loss in adenine. *Phys. Chem. Chem. Phys.* **6**, 5178-5183 (2004).

FIGURE LEGENDS

Fig. 1. Reactions catalyzed by MTTases. **a**, MiaB (CDK5RAP1). **b**, MtaB (CDKAL1). **c**, RimO. Each reaction requires two molecules of SAM, one of which is converted to SAH, and one of which is converted to 5'dAH + Met.

Fig. 2. RNA binding to *BuMiaB*. **a**, Domains of *BuMiaB* in complex with the 13-mer and 5'-dAH+Met in three different perspectives. The color code is the following: MTTase domain, tan; radical SAM domain, grey; TRAM domain, green. **b**, RNA recognition motifs in *BuMiaB*. Fo-Fc omit map contoured at 3.5σ showing electron density for U33 in the recognition pocket. **c**, Electrostatic potential of the U33 binding pocket. **d**, Fo-Fc omit map (1.5 Å resolution), contoured at 3.5σ , showing the electron density for A36 interacting with conserved Phe348 and Phe350 from the radical SAM domain. **e**, Electrostatic potential in the vicinity of A36.

Fig. 3. *BuMiaB* active site in the presence of RNA substrates. **a**, 13-mer + SAH (1.86 Å). **b**, 17-mer + SAM (2.25 Å). **c**, 13-mer + 5'dAH+Met (1.5 Å). Fo-Fc omit maps are contoured at 2.5σ in **a** and **b**, and at 3.5σ in **c**. **d**, Active site of pre-methylated *BuMiaB* in the presence of the 13-

mer RNA and 5'dAH+Met. The electron density is a Polder map contoured at 3.0σ and shown in gray for atoms of the cluster and green for the methyl group. Panels **a**, **b**, and **c** are all distinct views; however, panel **b** is rotated clockwise $\sim 90^\circ$ from panel **a**, and panel **c** is rotated clockwise $\sim 120^\circ$ from panel **b**. Residues from the MTTase domain are colored tan, while those from the radical SAM domain are colored gray.

Fig. 4. Proposed mechanism for the MiaB reaction. One molecule of SAM binds to the $[\text{Fe}_4\text{S}_4]_{\text{RS}}$ cluster and transfers a methyl group to a bridging μ_2 sulfido ion of the auxiliary cluster (**1**). SAH dissociates and another molecule of SAM binds to the $[\text{Fe}_4\text{S}_4]_{\text{RS}}$ cluster (**2**), which is followed by tRNA binding (**3**). The methylated sulfur of the $[\text{Fe}_3\text{S}_4]_{\text{aux}}$ attacks C2 of the substrate, forming a tetrahedral intermediate (**4**). Reduction of the $[\text{Fe}_4\text{S}_4]_{\text{RS}}$ cluster (**4**) promotes formation of the 5'-dA• (**5**), which abstracts the C2 hydrogen (**6**). Loss of an electron and rearomatization of the adenine ring (**7**) leads to an $[\text{Fe}_3\text{S}_3]^{1+}$ cluster containing a methylthio ligand, which dissociates (**8**) to give the final product.

EXTENDED DATA FIGURE LEGENDS

Extended Data Fig. 1. Comparison of *BuMiaB* and *TmRimO* structures. **a**, Cartoon overlay of the structures of *BuMiaB* (blue) and *TmRimO* (PDB:4JC0) (gray). **b**, Electrostatic surface potential of *TmRimO* (blue is positive, red is negative, and gray is neutral). **c**, Amino acid sequence alignment of *BuMiaB* and *TmRimO*. The overall architecture of *BuMiaB* is similar to that of *TmRimO*, with RMSDs of 1.5 and 1.6 Å for the two independent RimO molecules over 324 and 329 C α s, respectively (Table S1). In the RimO X-ray crystal structure, the two $[\text{Fe}_4\text{S}_4]$ clusters are 7.3 Å apart (nearest ion in each cluster) and are connected by a pentasulfide bridge

spanning the unique (non-cysteinylligated) irons of each cluster. This same pentasulfide bridge is observed in the *BuMiaB* structure, wherein the clusters are 6.8 Å apart (see **Extended Data Fig. 2a**).

Extended Data Fig. 2. RNA binds to all three domains in *BuMiaB*. **a**, Cartoon representation of the active site of *BuMiaB* with a pentasulfide bridge spanning the two [Fe₄S₄] clusters. MTTase domain, tan; radical SAM domain, gray; TRAM domain, green. **b**, Cartoon of *BuMiaB* crystallized in the presence of the 13-mer RNA substrate and 5'-dAH+Met and showing the binding of the 13-mer (purple) at the interface of the three domains. **c**, Electrostatic surface potential (blue is positive, red is negative, and gray is neutral) indicates a positively charged active-site region promoting binding of the 13-mer. **d**, Conservation of amino acids in the active-site region as deduced from the CONSURF server.³⁴

Extended Data Fig. 3. Comparison of ACSL structure in 13-mer bound to *BuMiaB* with full-length tRNA^{Phe} bound to *TmMiaA*. **a**, Cartoon overlay of the 13-mer (nucleotides 29-41) structure in the complex with *BuMiaB* and 5'-dAH+Met (purple color), with that of *Tm* tRNA^{Phe} in complex with *MiaA* (tan color) (**PDB ID: 2ZM5**). **b**, Schematic diagram of hydrogen bonds formed between the 13-mer and *BuMiaB*.

Extended Data Fig. 4. Comparison of ACSL structure in 17-mer bound to *BuMiaB* with full-length tRNA^{Phe} bound to *TmMiaA*. **a**, Cartoon overlay of the 13-mer (purple color) and 17-mer (nucleotides 27-43) (green color) structures in complex with *BuMiaB* plus 5'-dAH+Met (13-mer) or *BuMiaB* with SAM (17-mer), with that of *Tm* tRNA^{Phe} in complex with *MiaA* (tan color) (**PDB ID: 2ZM5**). **b**, Schematic diagram of the H-bonds formed between the 17-mer and *BuMiaB*.

Extended Data Fig. 5. Active site interactions of *BuMiaB* with nucleotides 34 and 35 of the anticodon. The structure of *BuMiaB* with the 13-mer RNA and 5'-dAH+Met is shown in pink, while the structure of *BuMiaB* with the 17-mer RNA and SAM is shown in maroon. **a**, Active site interactions with G34. G34 is often modified, and its base inserts between the TRAM and RS domains in a deep cleft, which provides space for modifications. In the structure of *BuMiaB* in complex with 5'-dAH+Met and the 13-mer, N¹⁰ of G34 is within H-bonding distance to Ser388 of the RS domain. The 2' and 3' OH groups are H-bonded to two nitrogen atoms from the guanidinium group of Arg418 from the TRAM-domain. In the structure of *BuMiaB* with SAM and the 17-mer, the position of G34 is different, and the base no longer interacts with Ser388 and Arg418 (**Extended Data Figs. 3b, 4b**). **b**, Active site interactions with A35. In the structure of *BuMiaB* with 5'-dAH+Met and the 13-mer, the carboxylate oxygens of Asp319 are within H-bonding distance to N⁶ of A35, while the side-chain of Gln28 is in H-bonding distance to the 2' OH of A35. The A35 base is π -stacked between Phe348 on one side and the adenine ring of i⁶A37 on the other. The position of A35 is shifted in the SAM-bound structure and is stabilized by π -stacking with G34 on one side and Phe348 on the other. The rotation of Phe348 supports two different orientations of A35 in the active site of the enzyme. **c**, Binding of i⁶A37 in the active site of *BuMiaB* in the structure with the 13-mer and 5'-dAH+Met, showing that the isopentenyl group sits in a hydrophobic patch. All figures have the same color for the domains and their associated residues: tan for MTTase, gray for radical SAM and green for TRAM.

Extended Data Fig. 6. A Model for full-length tRNA binding to *BuMiaB*. **a**, Conservation of residues in *BuMiaB* as deduced from the CONSURF server. The color code is described in the panel. **b**, Electrostatic surface potential, indicating positively charged regions that could stabilize

375 tRNA^{Phe}. **c**, A predicted model of interactions between the residues from the MTTase domain
376 and the full-length tRNA.

377 **Extended Data Fig. 7. Binding of SAM, SAH, and 5'-dAH to *BuMiaB*.** **a**, Overlay of SAM
378 (gray), SAH (aquamarine) and 5'-dAH+Met (light violet) in their complexes with *BuMiaB* and
379 RNA substrates (17-mer for SAM, and 13-mer for SAH or 5'-dAH+Met). The adenine ring of
380 SAM, SAH and 5'-dAH forms face-to-face π -stacking interactions with Phe321. This stacking is
381 further supported by edge-to-face interactions with two tyrosines (177, 352) and Phe350. N³ of
382 the adenine ring H-bonds with the conserved Arg66 (shown in **Fig. 3a**), and N⁶ forms three H-
383 bonds with the carbonyl groups of Ile65 (MTTase domain), and Tyr177 and Ser353 (RS
384 domain). The ribose moiety of SAM, SAH and 5'-dAH H-bonds with Arg66, Gln281 and
385 Asp319. Methionine in the 5'-dAH+Met structure or the methionine moiety of SAM (with the 17-
386 mer RNA) and SAH (with 13-mer RNA) in structures with those molecules bound shows the
387 canonical bidentate binding to the unique iron of the [Fe₄S₄]_{RS} cluster. **b**, Overlay of SAM (gray)
388 or 5'-dAH+Met (light violet) in complex with *BuMiaB* and the 17-mer RNA (SAM) or 13-mer
389 RNA (5'-dAH+Met). The i⁶A37 base is in pink for the structure with 5'-dAH+Met and maroon
390 for the structure with SAM. All figures have the same color for the domains and their associated
391 residues: tan for MTTase, gray for radical SAM and green for TRAM, except for Gln215 in the
392 structure with 5'-dAH+Met (panel a), which rotates.

393 **Extended Data Fig. 8. Effect of Arg66→Gln substitution on *BuMiaB* activity.** **a**, Time
394 course for SAH formation upon incubating 25 μ M *BuMiaB* WT (black circles) or *BuMiaB* R66Q
395 (red circles) with 1 mM SAM in the absence of dithionite. **b-e**, Time course for formation of
396 SAH (**b**), 5'-dAH (**c**), ms²i⁶A (**d**), and decay of i⁶A (**e**), after 30 min of initial incubation of 25 μ M
397 *BuMiaB* with 1 mM SAM followed by addition of 100 μ M i⁶A ACSL RNA and reaction

initiation with 1 mM dithionite. The black color corresponds to data obtained for *BuMiaB* WT in the presence of the 17-mer RNA substrate; the blue color corresponds to data obtained in the presence of the 13-mer; and the red color corresponds to data for *BuMiaB* R66Q in the presence of the 17-mer. Error bars represent one standard deviation for reactions conducted in triplicate, with the centre representing the mean.

Extended Data Fig. 9. Stereoscopic representation of the active site electron density of pre-methylated *BuMiaB* in the presence of the 13-mer RNA substrate and 5'dAH+Met. The structure of *BuMiaB* does not show any significant changes in the protein or RNA components of the complex in the pre-methylated versus non-pre-methylated states [RMSD = 0.231 Å (C_{α} = 371 atoms) and 0.089 Å (C_{α} = 439 atoms) for pre-methylated subunits A and B, respectively, versus non-pre-methylated subunit A; and 0.092 Å (C_{α} = 415 atoms) and 0.248 Å (C_{α} = 392 atoms) for pre-methylated subunits A and B, respectively, versus non-methylated subunit B]. **a**, The extended electron density at N³. The gray mesh corresponds to an Fo-Fc omit map for i⁶A contoured at 3.5 σ , and the green mesh to an Fo-Fc map contoured at 3.0 σ after refinement with i⁶A. **b**, The extended electron density at the sulfur atom of the [Fe₃S₄] cluster. The mesh corresponds to an Fo-Fc omit map for the methyl group (green color) attached to the sulfur (gray color) of the auxiliary cluster contoured at 3.5 σ . **c**, In a map generated for the non-pre-methylated auxiliary cluster, no extended density is observed. The mesh corresponds to an Fo-Fc omit map for the sulfur atom of the auxiliary cluster contoured at 3.5 σ . All residues have a common color theme for the domains: tan for MTTase and gray for radical SAM.

Extended Data Table 1. X-ray crystallographic data collection and refinement statistics.

*Values in parentheses represent the highest-resolution shell.

METHODS

Cloning of the gene encoding *BuMiaB* (native *BuMiaB* structure)

The gene encoding *BuMiaB* (Uniprot: A7UYY7) was amplified from *Bacteroides uniformis* (strain ATCC 8492) genomic DNA using the following forward and reverse primers, respectively: 5'-TACTTCCAATCCATGATGGAAAAAGTAACGGGAGCAGAC-3' and 5'-TATCCACCTTTACTGTTAGCCGGCTACCTCTTCTCCTTTC-3'. The PCR products were purified with the Agencourt Ampure XP PCR clean-up kit (Beckman Coulter) using the manufacturer's protocol. The pSGC vector was prepared for ligation-independent cloning (LIC) by linearization with the restriction enzyme *BsaI*. LIC sites were installed by adding T4 DNA polymerase (New England Biolabs, NEB) to 10 µg linearized plasmid in a 50 µL reaction containing 2.5 mM GTP, 1× NEB Buffer 2, and 1× bovine serum albumin (BSA) for 1 h at 22 °C. T4 DNA polymerase was heat-inactivated by incubation at 75 °C for 20 min. 2 µL of the PCR products were also treated with T4 DNA polymerase in a 10 µL reaction containing 2.5 mM CTP, 1× NEB Buffer 2, and 1× BSA for 1 h at 22 °C. T4 DNA polymerase was heat inactivated by incubation at 75 °C for 20 min. The LIC reaction was carried out by mixing 15 ng of digested vector with ~ 40 ng of digested PCR product with a subsequent incubation at 22 °C for 10 min. A 30 µL aliquot of DH10B cells (NEB) was used in a transformation along with 2 µL of the above mixture using standard protocols. Cloning the genes into pSGC with this method adds a hexahistidine tag with a TEV cleavage site to the N-terminus of the protein (MHHHHHHSSGVDLGTENLYFQS-protein). All final constructs were sequence-verified with dideoxy sequencing performed by Genescript. For expression, *E. coli* BL21(DE3) cells containing the pDB1282 plasmid were transformed with the above construct.³⁵ Transformants were selected on an LB agar plate containing 50 µg/mL kanamycin and 100 µg/mL ampicillin. A

single colony was used to inoculate 20 mL of LB which, after overnight incubation, was used to start 2 L of super broth expression media in a 2 L PYREX® media bottle. After 5 h of growth at 37 °C, cysteine and arabinose were added to final concentrations of 600 and 0.1 %, respectively. The cultures were incubated for an additional hour before being cooled to 22 °C. After ~ 20 h, the cells were harvested by centrifugation at 10,000 ×g, flash frozen, and stored in liquid nitrogen until purification.

Cloning and expression of the gene encoding *BuMiaB* (substrate-bound structures)

The second gene encoding *BuMiaB* (**A0A174NUT3**) was synthesized by GeneArt Life-technologies (www.lifetechnologies.com) (see supporting information for DNA and protein sequence) and was provided in a pMAT-plasmid inserted using *NdeI* and *EcoRI* restriction sites. The pMAT-*BuMiaB* plasmid was digested with *NdeI* and *EcoRI* and ligated into a similarly digested pET-28a plasmid by standard procedures.³⁶ The correct construct, which encodes MiaB containing an N-terminal hexahistidine tag separated from the native initial amino acid by a spacer of 10 aa, was verified by sequencing at the Penn State (University Park) Huck Genomics Core facility. The resulting expression vector, pET28-*BuMiaB*, was used along with plasmid pDB1282 to transform *E. coli* BL21 (DE3) as previously described.^{35,37} The encoded protein differs from the one used for the native *BuMiaB* structure by one amino acid change: A0A174NUT3 contains His at position 363, while A7UYY7 contains Tyr.

Bacterial growth and gene expression were carried out at 37 °C in 16 L of LB media distributed evenly among 4 Erlenmeyer flasks with moderate shaking (180 rpm). At an optical density (OD) of 0.3 at 600 nm (OD₆₀₀), solid *L*-(+)-arabinose was added to each flask to a final concentration of 0.2 % (w/v), while cysteine and ferric chloride were added to final

concentrations of 300 μ M and 50 μ M, respectively. At an OD₆₀₀ of 0.6, solid isopropyl β -D-thiogalactopyranoside (IPTG) was added to each flask to a final concentration of 500 μ M. Expression was allowed to take place for 16 h at 18 °C before the cells were harvested by centrifugation at 7,000 \times g for 12 min at ambient temperature. The cell paste was frozen and stored under liquid nitrogen.

Purification of *BuMiaB*

BuMiaB was purified under anoxic conditions in a Coy (Grass Lakes, MI) anaerobic glovebox, which was filled with a mixture of N₂ (95%) and H₂ (5%) and maintained below 1 ppm O₂ using palladium catalysts. *BuMiaB* was purified by immobilized metal affinity chromatography (IMAC) using Ni-NTA resin (Qiagen). 30 g cell paste was suspended in 100 mL lysis buffer (50 mM HEPES, pH 7.5, 300 mM KCl, 10 mM MgCl₂, 10 mM 2-mercaptoethanol, 10 mM imidazole, 1 mg/mL lysozyme), placed in a metal cup, and incubated in an ice-water bath for 30 min. The cells were then subjected to a series of bursts of sonic disruption in the glovebox while maintaining the cell suspension at \leq 8 °C. The cell suspension was transferred into sterile centrifuge tubes, which were subsequently sealed, removed from the anaerobic chamber and centrifuged at 45,000 \times g for 1 h at 4 C°. The supernatant was loaded onto a Ni-NTA column (30 ml), which was subsequently washed with an appropriate volume of wash buffer (50 mM HEPES, pH 7.5, 300 mM KCl, 10 mM MgCl₂, 10 mM 2-mercaptoethanol, 20 mM imidazole). *BuMiaB* was eluted from the resin using elution buffer (50 mM HEPES, pH 7.5, 300 mM KCl, 10 mM MgCl₂, 10 mM 2-mercaptoethanol, 250 mM imidazole). Fractions containing *BuMiaB*, distinguished by their dark brown color, were pooled and concentrated using Amicon Ultracel – 10 K centrifugal filters (Millipore, Billerica, MA). The protein was

exchanged into storage buffer (50 mM HEPES, pH 7.5, 150 mM KCl, 20% glycerol, 10 mM MgCl₂, 1 mM DTT), snap frozen in small aliquots in liquid nitrogen and stored under liquid nitrogen.

To ensure complete Fe/S cluster content, *BuMiaB* (0.1 mM) was subjected to reconstitution by incubating it with an 8-fold molar excess of FeCl₃ and Na₂S, at 4 °C overnight, as described previously.^{35,37} The protein was concentrated using centrifugal filters and applied to an S-200 size-exclusion column connected to an ÄKTA liquid chromatography system (GE Biosciences) housed in an anaerobic glovebox. The column was equilibrated in storage buffer at a flow rate of 0.5 ml/min before injecting the protein and eluting it at the same flow rate. Fractions were chosen based on their brown color, elution time and having both an absorbance at 280 nm (protein) and at 400 nm (Fe/S cluster).

Preparation of RNA substrates

An oligoribonucleotide substrate corresponding to the 17-nucleotide (17-mer) anticodon stem-loop (ACSL) of *Bu* tRNA^{Phe} (5'-AAGGACUGAAA**A**UCCUU-3') was synthesized by Dharmacon Thermo Fisher Scientific (Lafayette, CO). Nucleotide A37, shown in bold, is the site of modification by MiaA and MiaB. *E. coli* MiaA was used to transfer a dimethylallyl group from dimethylallyl pyrophosphate to N⁶ of A37 as described previously.⁶ A 13-mer from the ACSL of *Bu* tRNA^{Phe} (5'-GGACUGAA(i6)**A**AUCC-3') was also synthesized by Dharmacon Thermo Fisher Scientific. In this instance, the i⁶A modified based was synthesized chemically, as described previously,⁶ and then supplied to Dharmacon for incorporation into the oligonucleotide.

Crystallization of native *BuMiaB*

Diffraction-quality crystals of *BuMiaB* were obtained by the sitting-drop vapor diffusion method at 20 °C in an anaerobic chamber maintained at < 0.1 ppm oxygen (MBraun, Stratham, NH). Drops of 0.4 µL protein solution (TEV-cleaved *BuMiaB* diluted to 5 mg•mL⁻¹ in 10 mM HEPES, pH 7.5, 10 mM DTT) were mixed with 0.4 µL precipitant (0.2 M potassium formate, pH 7.3, 20% polyethylene glycol 3350) and equilibrated against a solution of 0.5 M LiCl. The crystals were mounted directly from the drops with nylon loops and flash-cooled in liquid nitrogen inside the anaerobic chamber, and stored in liquid nitrogen prior to data collection. Diffraction data were collected at the Advanced Photon Source (Argonne National Laboratory, Argonne IL) on beamline 23-ID-D (GMCA) at 100 K and were integrated and scaled using HKL3000.³⁸ A 2.06 Å resolution dataset was collected at a wavelength of 1.078 Å. Phases were determined by molecular replacement using RimO (PDB 2QGQ) as the search model.⁸ This initial model was then refined with rounds of automated model building performed by Phenix AutoBuild,³⁹ interspersed with manual model building and refinement using Coot,⁴⁰ phenix.refine.⁴¹ The final model comprises a single polypeptide chain containing amino acid residues 16 to 65 and 72 to 457 out of a total of 457 residues. The model also contains 2 [Fe₄S₄] clusters, a Mg²⁺ ion, and a pentasulfide bridge. Validation of the model was performed with MolProbity.⁴² The Ramachandran plot shows that 97.4% of residues are in favored regions, with the remaining 1.6% in allowed regions. Full data processing, refinement, and validation details are in **Extended Data Table 1**.

Crystallization of *BuMiaB* in the presence of substrates

BuMiaB (10 mg/mL), in a buffer containing 15 mM HEPES, pH 7.5, 100 mM KCl, 5 mM DTT and 10 mM MgCl₂, was incubated at room temperature first with 1 mM SAM for 30 min, and subsequently with a 1:1.3 ratio of *BuMiaB* to the 17-mer RNA substrate for 30 additional min. The solution of the protein/RNA complex was passed through a 0.2 µm sterile centrifugal filter (EMD Millipore, Billerica, MA). Crystals of the complex were obtained from 100 mM Na-cacodylate, pH 5.5, 13% PEG 4000 and 3% (+/-)-2-methyl-2,4-pentanediol or 1% of 1,2-butanediol as additives, which was also used in the well, with the exception of the (+/-)-2-methyl-2,4-pentanediol or 1% of 1,2-butanediol. Diffraction datasets were collected at the Advanced Photon Source (Argonne National Laboratory, Argonne IL) on beamline 23-ID-B (GMCA) at 100 K and at a wavelength of 1.033 Å. The Ramachandran plot shows that 97.4% of residues are in favored regions, with 3.4% in allowed regions and 0.2% as outliers.

To generate the *BuMiaB* complex with RNA+SAH, *BuMiaB* was first incubated with 1 mM SAH for 30 min, and subsequently with a 1:1.3 ratio of *BuMiaB* with the 17-mer or 13-mer RNA RNA substrate for 30 additional min. Crystals exhibiting the best diffraction grew in three days from the condition containing 100 mM Na-cacodylate, pH 5.5, 13% PEG 4000 and 3% 1,6-hexanediol, which was also used in the well, with the exception of the 1,6-hexanediol. Diffraction datasets were collected at the Advanced Photon Source (Argonne National Laboratory, Argonne IL) on beamline 23-ID-B (GMCA) at 100 K and at a wavelength of 1.033 Å. The Ramachandran plot shows that 98.2% of residues are in favored regions, with the remaining 1.8% in allowed regions.

The crystallization conditions for the complex of *BuMiaB* with the 13-mer and 5'dAH+Met were the same as those for the *BuMiaB* structure with SAM and the 17-mer. *BuMiaB* was first incubated with methionine for 15 min, and subsequently with 5'-dAH for 30

min, before incubating it with a 1:1.3 ratio of the protein to the 13-mer for 30 min. Diffraction datasets were collected at the Advanced Photon Source (Argonne National Laboratory, Argonne IL) on beamline 23-ID-B (GMCA) at 100 K and at a wavelength of 1.033 Å. The Ramachandran plot shows that 97.6% of residues are in favored regions, with the remaining 2.4% in allowed regions.

Crystallization of pre-methylated *BuMiaB*

BuMiaB (200 µM) was incubated with 1 mM SAM for 45 min, and then excess SAM was removed by gel-filtration chromatography. This protein was then mixed with 5 mM Met, 1 mM 5'-dAH and the 13-mer RNA substrate (250 µM) for crystallization. Crystals formed in three days in the same crystallographic conditions as for the non-methylated enzyme. Diffraction datasets were collected at the Advanced Photon Source (Argonne National Laboratory, Argonne IL) on beamline 23-ID-B (GMCA) at 100 K and at a wavelength of 1.033 Å. The structure of the pre-methylated *BuMiaB* with 5'-dAH+Met and the 13-mer RNA was determined at a resolution of 1.4 Å. A Ramachandran plot of the final model shows that 97.6% of residues are in favored regions, with the remaining 2.4% in allowed regions (**Extended Data Table 1**). The structure does not show any significant changes in the protein or RNA components of the complex in the methylated versus unmethylated states [RMSD = 0.231 Å (C_{α} = 371 atoms) and 0.089 Å (C_{α} = 439 atoms) for methylated subunits A and B, respectively, versus unmethylated subunit A; and 0.092 Å (C_{α} = 415 atoms) and 0.248 Å (C_{α} = 392 atoms) for methylated subunits A and B, respectively, versus unmethylated subunit B].

Modeling of *BuMiaB* with full-length tRNA

The crystal structures of *BuMiaB* with 5'-dAH+Met and the bound 13-mer RNA substrate were used as a guide for building a model of the complex of *BuMiaB* with the full-length tRNA. The structure of the tRNA-modifying enzyme MiaA in complex with tRNA^{Phe} (PDB: 2ZM5) served as the starting model. The ACSL base-pairing within the helical stem of the full-length tRNA was aligned onto the 13-mer RNA in the structure of *BuMiaB* with 5'-dAH+Met. The model of the tRNA^{Phe}+*BuMiaB* complex was guided by conserved residues and positive electrostatic surface potential favorable for the RNA phosphate backbone contacts (Fig. S7).

Generation of the Arg66Gln *BuMiaB* variant and subsequent activity measurements

The Arg66Gln variant of *BuMiaB* was generated using the Stratagene Quikchange site-directed mutagenesis kit according to the manufacturer's protocol. The pET28-*BuMiaB* construct was used as a template in conjunction with a forward primer (5'-GAATACCTGTAGCATTTCAGGATAACGCCGAACAG-3') and a reverse primer (5'-CTGTTTCGGCGTTATCCTGAATGCTACAGGTATTC-3'). Activity measurements of *BuMiaB* WT and *BuMiaB*-R66Q were conducted as previously described using the 17-mer or 13-mer oligonucleotide substrate from the ACSL of *Bu* tRNA^{Phe} (Fig. S9).⁶

ADDITIONAL REFERENCES

- 34 Ashkenazy, H. *et al.* ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules. *Nucleic Acids Res* **44**, W344-350, doi:10.1093/nar/gkw408 (2016).

- 35 Lanz, N. D. *et al.* RlmN and AtsB as models for the overproduction and characterization of radical SAM proteins. *Methods Enzymol.* **516**, 125-152, doi:10.1016/B978-0-12-394291-3.00030-7 (2012).
- 36 Sambrook, J., Fritsch, E. F. & Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd edn, Vol. 3 (Cold Spring Harbor Laboratory Press, 1989).
- 37 McCarthy, E. L. & Booker, S. J. Biochemical approaches for understanding iron-sulfur cluster regeneration in *Escherichia coli* lipoyl synthase during catalysis. *Methods Enzymol* **606**, 217-239 (2018).
- 38 Minor, W., Cymborowski, M., Otwinowski, Z. & Chruszcz, M. HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes. *Acta crystallographica. Section D, Biological crystallography* **62**, 859-866, doi:10.1107/S0907444906019949 (2006).
- 39 Terwilliger, T. C. *et al.* Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. *Acta crystallographica. Section D, Biological crystallography* **64**, 61-69, doi:10.1107/S090744490705024X (2008).
- 40 Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 486–501 (2010).
- 41 Afonine, P. V. *et al.* Towards automated crystallographic structure refinement with phenix.refine. *Acta crystallographica. Section D, Biological crystallography* **68**, 352-367, doi:10.1107/S0907444912001308 (2012).
- 42 Williams, C. J. *et al.* MolProbity: More and better reference data for improved all-atom structure validation. *Protein Sci* **27**, 293-315, doi:10.1002/pro.3330 (2018).

ACKNOWLEDGMENTS

Funding Sources

This work was supported by NIH (GM-122595 to S.J.B; AI133329, to S.C.A. and T.L.G.; GM-127079 to C.K.; and GM118393, GM093342, and GM094662 to S.C.A.), NSF (MCB-1716686 to S.J.B.), the Eberly Family Distinguished Chair in Science (S.J.B.), The Price Family Foundation (S.C.A), and the Penn State Huck Institutes of the Life Sciences (N.H.Y.). S.J.B. is an investigator of the Howard Hughes Medical Institute. This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No.

DE-AC02-06CH11357. Use of GM/CA@APS has been funded in whole or in part with Federal funds from the National Cancer Institute (ACB-12002) and the National Institute of General Medical Sciences (AGM-12006). The Eiger 16M detector at GM/CA-XSD was funded by NIH grant S10 OD012289. Use of the LS-CAT Sector 21 was supported by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor (Grant 085P1000817). This research also used the resources of the Berkeley Center for Structural Biology supported in part by the Howard Hughes Medical Institute. The Advanced Light Source is a Department of Energy Office of Science User Facility under Contract No. DE-AC02-05CH11231. The ALS-ENABLE beamlines are supported in part by the National Institutes of Health, National Institute of General Medical Sciences, grant P30 GM124169.

Author contributions: O.A.E., T.L.G., N.H.Y., and S.J.B. developed the research plan and experimental strategy. O.A.E. and T.L.G. isolated and crystallized proteins and collected crystallographic data. O.A.E., B.W., and A.J.A. performed biochemical experiments. O.A.E., T.L.G., N.H.Y., S.C.A. C.K. and S.J.B. analyzed and interpreted crystallographic data. O.A.E., T.L.G., N.H.Y., and S.J.B. wrote the manuscript, while all other authors reviewed and commented on it.

The authors declare no competing interests

Additional Information: supplementary information is available for this paper.

Correspondence and requests for materials should be addressed to Squire J. Booker
(squire@psu.edu)

Data Availability: Atomic coordinates and structure factors for the reported crystal structures in this work have been deposited to the Protein Data Bank (PDB) under accession numbers 7MJZ (native structure with pentasulfide bridge), 7MJY (structure with SAH and 13-mer RNA), 7MJV (structure with SAM and 17-mer RNA), 7MJX (structure with 5'-dAH+Met and 13-mer RNA), and 7MJW (structure with pre-methylated *BuMiaB* and 5'-dAH+Met and 13-mer RNA).

ORCID

Squire J. Booker: 0000-0002-7211-5937

Olga A. Esakova: 0000-0001-8377-8368

Tyler L. Grove: 0000-0002-4763-0646


Arthur J. Arcinas: 0000-0003-4903-3500






Steven C. Almo: 0000-0003-2591-5234





Bo Wang: 0000-0002-0381-3686


Neela H. Yennawar: 0000-0001-7278-659X

Carsten Krebs: 0000-0002-3302-7053









Supplementary Information for

“Structural basis for tRNA methylthiolation by the radical SAM enzyme MiaB”

Authors: Olga A. Esakova^{1,*}, Tyler L. Grove^{2,*}, Neela H. Yennawar⁴, Arthur J. Arcinas^{3,6}, Bo Wang¹, Carsten Krebs^{1,3}, Steven C. Almo², and Squire J. Booker^{1,3,5*}

Affiliations: The ¹Department of Chemistry, the ³Department of Biochemistry and Molecular Biology, ⁴The Huck Institutes of the Life Sciences, and the ⁵Howard Hughes Medical Institute, The Pennsylvania State University, University Park, Pennsylvania 16802, USA.

The ²Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York

⁶Present address: AGC Biologics, Seattle, WA

Corresponding authors: squire@psu.edu, oe3@psu.edu, and tylergrove223@gmail.com

Table of Contents

1. Table S1
2. Figure S1
3. Figure S2

Table S1: The root mean square deviation (RMSD) for each model against the structure of *BuMiaB* with a pentasulfide was calculated using The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC

Structure	PDB entry	Chain	RMSD (Å) <i>Main chain</i>
<i>Bacteroides uniformis</i> MiaB with pentasulfide bridge	7MJZ	A	reference
<i>Thermatoga maritima</i> RimO	4JC0	A	1.6
		B	1.5
<i>Bacteroides uniformis</i> MiaB co-crystallized with SAH and 13-mer ACSL tRNA ^{Phe}	7MJY	A	0.4
<i>Bacteroides uniformis</i> MiaB co-crystallized with SAM and 17-mer ACSL tRNA ^{Phe}	7MJV	A	0.4
<i>Bacteroides uniformis</i> MiaB co-crystallized with 5'dAH+Met and 13-mer ACSL tRNA ^{Phe}	7MJX	A	0.9
		B	1.0
Methylated <i>Bacteroides uniformis</i> MiaB co-crystallized with 5'dAH+Met and 13-mer ACSL tRNA ^{Phe}	7MJW	A	1.0
		B	0.9



a

18 β_1 25 28 α_2 42 β_3 46 48 57 β_4 62 66 α_5

1 - MEKVTGADFKSATAD DNKKLFIETYGC QMNVADSEVIASVMQMAGYSVADTLEEADAVFMNTCSIRDNAEQKILNRLEFF - 80

83 β_6 90 95 97 α_7 102 104 109 α_8 114 116 β_9 121 α_{10} 133 137 139 β_{11}

81 - HSLKKKKRGLIVGVLG CMAERVKDDLITNHHVDLVV GPDAYLTLPELIASVEAGEKAMN - 139



b

β_{12} 166 α_{13} 179 184 193 α_{14} 205 β_{15} 209 213 α_{16} 217 219 β_{17} 224 227 231 β_{18} α_{19}



162 - SGFVSIMRGCNNFC TYCIVPYTRGRERSRDVESILNEVADLVAK GYKEVTLLGQNVNSYRFEKPDGETITFPMLLRVAEAA - 243

β_{20} 247 251 α_{21} 259 268 β_{22} 275 277 α_{23} 285 291 295 α_{24} 310 315 β_{25}

244 - PGVRIRFTTSHPKDMSDETLQVIADMPNVCKHIHLPVQSGSSRILKLMNRKYDREWYMDRVAAIRRIIPDCGLSTDIFSGFHS - 326

α_{26} 328 342 346 351 β_{27} α_{28} 359 363 369 α_{29} 395

327 - ETEEDHQLSLSLMEECGYDSAFMFKYSERPGTHASKHLPDDVPEEVKIRRLNEIIALQNRLSAEANARCV - 396






Fig. S1. Sequence, secondary structure schematic, and cartoon of the three-dimensional fold of *BuMiaB*. **a**, N-terminal MTTase domain. **b**, radical SAM domain. **c**, C-terminal TRAM domain. Beta sheets and alpha-helices in the schematics are represented in green and blue colors respectively. The radical SAM domain exhibits a conserved core fold that consists of a shortened $(\beta\alpha)_6$ triosephosphate isomerase (TIM) barrel, and contains four short alpha helical extensions (α_{13} , α_{16} , α_{23} and α_{28}) that make interactions with the cluster binding loop (residues from 167 to 178), as well as a solvent-exposed two-stranded β -sheet (β_{17} - β_{18}). All figures have the same color scheme for the domains and their associated residues: tan for MTTase, gray for radical SAM and green for TRAM. The cysteine residues involved in coordination of the clusters are colored in red.

a .

DNA

ATGGAAAAAGTTACCGGTGCCGATTTCAAAAGCGCAACCGCAGATGATAACAAAAAGCTGTTTATTGAAAC
CTACGGCTGCCAGATGAATGTTGCAGATAGCGAAGTTATTGCAAGCGTTATGCAGATGGCAGGTTATAGCG
TTGCGGATACCCTGGAAGAGGCAGATGCAGTTTTTATGAATACCTGTAGCATTTCGCGATAACGCCGAACAG
AAAATTCTGAATCGTCTGGAATTTTTCCACAGCCTGAAAAAAAAGAAACGCGGTCTGATTGTTGGTGTCT
GGGTTGTATGGCAGAACGTGTTAAAGATGATCTGATCACCAATCATCATGTGGATCTGGTTGTTGGTCCGG
ATGCATATCTGACCCTGCCGGAAGTATTGCCAGCGTTGAAGCCGGTGAAAAAGCAATGAATGTGGAACTG
AGCACCACCGAAACCTATCGTGATGTTATTCGAGCCGTATTTGCGGTAAATCATATTAGCGGTTTTGTGAG
CATTATGCGTGGCTGTAATAACTTTTGCACCTATTGCATTGTTCCGTATACACGTGGTCGTGAACGTAGCC
GTGATGTTGAAAGCATTCTGAATGAAGTTGCCGATCTGGTGGCAAAAGGTTATAAAGAAGTTACCCTGCTG
GGTCAGAATGTGAATAGCTATCGTTTTGAAAAACCGGATGGTGAAACCATTACCTTTCCGATGCTGCTGCG
TACCGTTGCCGAAGCAGCACCGGGTGTTCGTATTCGTTTTACCACCAGTCATCCGAAAGATATGAGTGATG
AAACCCTGCAGGTTATTGCAGATATGCCGAATGTGTGCAAACATATTCATCTGCCGGTTCAGAGCGGTAGC
AGCCGTATTCTGAACTGATGAATCGTAAATATGATCGCGAGTGGTATATGGATCGTGTTGCAGCAATTTCG
TCGTATTATTCGGGATTGTGGTCTGAGCACCGATATCTTTAGTGGTTTTCATAGCGAAACCGAAGAAGATC
ATCAGCTGAGCCTGAGTCTGATGGAAGAATGTGGTTATGATAGCGCCTTCATGTTCAAATATAGCGAACGT
CCGGGTACACATGCAAGCAAACATCTGCCTGATGATGTTCCGGAAGAAGTTAAAATTCGTCGCCTGAATGA
AATTATTGCCCTGCAGAAATCGCCTGAGTGCGGAAGCAAATGCACGTTGTGTTGGTAAAACCTATGAAGTTC
TGGTTGAAGGTGTTAGCAAACGTTACGTTGATCAGCTGTTTGGTTCGTACAGAACAGAAATCGTGTTGTTGTT
TTTGATCGTGGCACCCATCGTGTGGGTGATTTTGTTATGGTTAAAGTGACCGAAAGCAGCAGCGCAACCCT
GAAAGGTGAAGAAGTTGCAGGTTAA

b.

Protein:

MEKVTGADFKSATADDNKKLFIETYGCQMNVDSEVIASVMQMAGYSVADTLEEADAVFMNTCSIRDNAEQKILNRLE
FFHSLKKKKRGLIVGVLGCMAERVKDDLITNHHVDLVGPDAYLTLPELIASVEAGEKAMNVELSTTETYRDVIPSR
CGNHISGFVSIMRGCNNFCTYCIYPYTRGRERSRDVESILNEVADLVAKGYKEVTLLGQNVNSYRFEKPDGETITFPM
LLRTVAEAAAPGVRIRFTTSHPKDMSDETLQVIADMPNVCKHIHLPVQSGSSRIKLKLMNRKYDREWYMDRVAAIRRIIP
DCGLSTDIFSGFHSETEEDHQLSLSLMEECGYDSAFMFKYSERPGTHASK^{His363}LPDDVPEEVKIRRLNEIIALQNRLSAE
ANARCVGKTYEVLVEGVSKRSRDQLFGRTEQNRVVVFDRGTHRVGDFVMVKVTESSATLKGEVAG*

Fig. S2. *BuMiaB* DNA and protein sequences for structures with substrates. a, DNA sequence. **b,** Protein sequence. Note that His363 (shown in red) is Y363 in the native *BuMiaB* structure